171 related articles for article (PubMed ID: 36303665)
21. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.
Armstrong E; Hemmerling A; Miller S; Burke KE; Newmann SJ; Morris SR; Reno H; Huibner S; Kulikova M; Nagelkerke N; Coburn B; Cohen CR; Kaul R
Lancet Microbe; 2022 Jun; 3(6):e435-e442. PubMed ID: 35659905
[TBL] [Abstract][Full Text] [Related]
22. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections.
Witkin SS; Mendes-Soares H; Linhares IM; Jayaram A; Ledger WJ; Forney LJ
mBio; 2013 Aug; 4(4):. PubMed ID: 23919998
[TBL] [Abstract][Full Text] [Related]
23. Associations between the vaginal microbiome and Candida colonization in women of reproductive age.
Tortelli BA; Lewis WG; Allsworth JE; Member-Meneh N; Foster LR; Reno HE; Peipert JF; Fay JC; Lewis AL
Am J Obstet Gynecol; 2020 May; 222(5):471.e1-471.e9. PubMed ID: 31654610
[TBL] [Abstract][Full Text] [Related]
24. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.
Plummer EL; Bradshaw CS; Doyle M; Fairley CK; Murray GL; Bateson D; Masson L; Slifirski J; Tachedjian G; Vodstrcil LA
PLoS One; 2021; 16(2):e0246953. PubMed ID: 33571286
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis.
Sewankambo N; Gray RH; Wawer MJ; Paxton L; McNaim D; Wabwire-Mangen F; Serwadda D; Li C; Kiwanuka N; Hillier SL; Rabe L; Gaydos CA; Quinn TC; Konde-Lule J
Lancet; 1997 Aug; 350(9077):546-50. PubMed ID: 9284776
[TBL] [Abstract][Full Text] [Related]
26. Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.
Kyongo JK; Crucitti T; Menten J; Hardy L; Cools P; Michiels J; Delany-Moretlwe S; Mwaura M; Ndayisaba G; Joseph S; Fichorova R; van de Wijgert J; Vanham G; Ariën KK; Jespers V
Clin Vaccine Immunol; 2015 May; 22(5):526-38. PubMed ID: 25761460
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study.
Masson L; Barnabas S; Deese J; Lennard K; Dabee S; Gamieldien H; Jaumdally SZ; Williamson AL; Little F; Van Damme L; Ahmed K; Crucitti T; Abdellati S; Bekker LG; Gray G; Dietrich J; Jaspan H; Passmore JS
Sex Transm Infect; 2019 Feb; 95(1):5-12. PubMed ID: 30018088
[TBL] [Abstract][Full Text] [Related]
28. Surfactant Protein D Reverses the Gene Signature of Transepithelial HIV-1 Passage and Restricts the Viral Transfer Across the Vaginal Barrier.
Pandit H; Kale K; Yamamoto H; Thakur G; Rokade S; Chakraborty P; Vasudevan M; Kishore U; Madan T; Fichorova RN
Front Immunol; 2019; 10():264. PubMed ID: 30984160
[TBL] [Abstract][Full Text] [Related]
29. Immunometabolic Analysis of
McKenzie R; Maarsingh JD; Łaniewski P; Herbst-Kralovetz MM
Front Cell Infect Microbiol; 2021; 11():759697. PubMed ID: 35004344
[TBL] [Abstract][Full Text] [Related]
30. Temporal Changes in Vaginal Microbiota and Genital Tract Cytokines Among South African Women Treated for Bacterial Vaginosis.
Mtshali A; San JE; Osman F; Garrett N; Balle C; Giandhari J; Onywera H; Mngomezulu K; Mzobe G; de Oliveira T; Rompalo A; Mindel A; Abdool Karim SS; Ravel J; Passmore JS; Abdool Karim Q; Jaspan HB; Liebenberg LJP; Ngcapu S
Front Immunol; 2021; 12():730986. PubMed ID: 34594336
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
[TBL] [Abstract][Full Text] [Related]
32. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth.
Witkin SS
BJOG; 2015 Jan; 122(2):213-8. PubMed ID: 25316066
[TBL] [Abstract][Full Text] [Related]
33. Vaginal microbiome: normalcy vs dysbiosis.
Saraf VS; Sheikh SA; Ahmad A; Gillevet PM; Bokhari H; Javed S
Arch Microbiol; 2021 Sep; 203(7):3793-3802. PubMed ID: 34120200
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis.
Aldunate M; Srbinovski D; Hearps AC; Latham CF; Ramsland PA; Gugasyan R; Cone RA; Tachedjian G
Front Physiol; 2015; 6():164. PubMed ID: 26082720
[TBL] [Abstract][Full Text] [Related]
35. Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility.
Joag V; Obila O; Gajer P; Scott MC; Dizzell S; Humphrys M; Shahabi K; Huibner S; Shannon B; Tharao W; Mureithi M; Oyugi J; Kimani J; Kaushic C; Ravel J; Anzala O; Kaul R
Clin Infect Dis; 2019 May; 68(10):1675-1683. PubMed ID: 30407498
[TBL] [Abstract][Full Text] [Related]
36. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat.
D'Cruz OJ; Uckun FM
Toxicol Pathol; 2007 Dec; 35(7):910-27. PubMed ID: 18098038
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Lactobacillus crispatus isolates from Lactobacillus-dominated vaginal microbiomes with isolates from microbiomes containing bacterial vaginosis-associated bacteria.
Abdelmaksoud AA; Koparde VN; Sheth NU; Serrano MG; Glascock AL; Fettweis JM; Strauss JF; Buck GA; Jefferson KK
Microbiology (Reading); 2016 Mar; 162(3):466-475. PubMed ID: 26747455
[TBL] [Abstract][Full Text] [Related]
38. Why do lactobacilli dominate the human vaginal microbiota?
Witkin SS; Linhares IM
BJOG; 2017 Mar; 124(4):606-611. PubMed ID: 28224747
[TBL] [Abstract][Full Text] [Related]
39. Host and Microbiome Interplay Shapes the Vaginal Microenvironment.
Kwon MS; Lee HK
Front Immunol; 2022; 13():919728. PubMed ID: 35837395
[TBL] [Abstract][Full Text] [Related]
40. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
